JP2008531604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531604A5 JP2008531604A5 JP2007557300A JP2007557300A JP2008531604A5 JP 2008531604 A5 JP2008531604 A5 JP 2008531604A5 JP 2007557300 A JP2007557300 A JP 2007557300A JP 2007557300 A JP2007557300 A JP 2007557300A JP 2008531604 A5 JP2008531604 A5 JP 2008531604A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- glucopyranoso
- pyrano
- thiazoline
- dideoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 15
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 13
- -1 acetoxymethyl Chemical group 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- YQHOHPOCZUAUKP-UHFFFAOYSA-N n-[(aminooxy)carbonyl]aniline Chemical compound NOC(=O)NC1=CC=CC=C1 YQHOHPOCZUAUKP-UHFFFAOYSA-N 0.000 claims 6
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 claims 5
- AREJBZPGVDSCFV-LMHBHQSJSA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-(2-methylpropyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CC(C)C)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O AREJBZPGVDSCFV-LMHBHQSJSA-N 0.000 claims 5
- QWLSGKMXAHXJDM-LMHBHQSJSA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-butyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CCCC)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O QWLSGKMXAHXJDM-LMHBHQSJSA-N 0.000 claims 5
- PFPXOCGKVAYLDW-DIAXPKBXSA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-ethyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CC)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O PFPXOCGKVAYLDW-DIAXPKBXSA-N 0.000 claims 5
- COARJWAHYFNYJD-JVNHZCFISA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-pentyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CCCCC)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O COARJWAHYFNYJD-JVNHZCFISA-N 0.000 claims 5
- QZKZZLAADHHBPD-UTGUJQJDSA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-propan-2-yl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(C(C)C)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O QZKZZLAADHHBPD-UTGUJQJDSA-N 0.000 claims 5
- VRJFQCRQLPVYQE-JPIRQXTESA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-propyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CCC)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O VRJFQCRQLPVYQE-JPIRQXTESA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000004770 neurodegeneration Effects 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 4
- VUWIPARUGVLNEP-NENRSDFPSA-N (3ar,5r,6s,7r,7ar)-2-butyl-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(CCCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O VUWIPARUGVLNEP-NENRSDFPSA-N 0.000 claims 3
- ACNLJPLCGRIHJF-GPMKSPRZSA-N (3ar,5r,6s,7r,7ar)-2-ethyl-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(CC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O ACNLJPLCGRIHJF-GPMKSPRZSA-N 0.000 claims 3
- DRHXTSWSUAJOJZ-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(C)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O DRHXTSWSUAJOJZ-FMDGEEDCSA-N 0.000 claims 3
- QWOPEBCGKASVQP-QXOHVQIXSA-N (3ar,5r,6s,7r,7ar)-5-(hydroxymethyl)-2-propyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(CCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O QWOPEBCGKASVQP-QXOHVQIXSA-N 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- HFGXRMOCEYNLGH-DHGKCCLASA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-methyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]2SC(C)=N[C@@H]21 HFGXRMOCEYNLGH-DHGKCCLASA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 2
- 229940124639 Selective inhibitor Drugs 0.000 claims 2
- UIPOTIGLSUPBEG-VBSBHUPXSA-N [(2R,3S,4R,5R)-3,4-diacetyloxy-6-(phenylcarbamoyloxyimino)-5-(propanoylamino)oxan-2-yl]methyl acetate Chemical compound CCC(=O)N[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC1=NOC(=O)NC1=CC=CC=C1 UIPOTIGLSUPBEG-VBSBHUPXSA-N 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 125000006755 (C2-C20) alkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ITVRELFVFCOUMV-NMFUWQPSSA-N [[(3r,4r,5s,6r)-3-(butanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 ITVRELFVFCOUMV-NMFUWQPSSA-N 0.000 claims 1
- VIUUSOMOWDCFGS-MWQQHZPXSA-N [[(3r,4r,5s,6r)-3-(hexanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 VIUUSOMOWDCFGS-MWQQHZPXSA-N 0.000 claims 1
- QIDNPKQVOUOABR-AAVRWANBSA-N [[(3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(2-methylpropanoylamino)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CC(C)C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 QIDNPKQVOUOABR-AAVRWANBSA-N 0.000 claims 1
- CNCUWUMEUHOGHK-DTZQCDIJSA-N [[(3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(3-methylbutanoylamino)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CC(C)CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 CNCUWUMEUHOGHK-DTZQCDIJSA-N 0.000 claims 1
- NUNQIQQEEPOGDJ-DTZQCDIJSA-N [[(3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(pentanoylamino)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 NUNQIQQEEPOGDJ-DTZQCDIJSA-N 0.000 claims 1
- ADGOMNHDQHIKMZ-FMKGYKFTSA-N [[(3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(propanoylamino)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 ADGOMNHDQHIKMZ-FMKGYKFTSA-N 0.000 claims 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 claims 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 244000144992 flock Species 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940005605 valeric acid Drugs 0.000 claims 1
- 0 *C[C@]([C@]1O)O[C@]2NC(*)=*[C@@]2[C@]1O Chemical compound *C[C@]([C@]1O)O[C@]2NC(*)=*[C@@]2[C@]1O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65687805P | 2005-03-01 | 2005-03-01 | |
| US60/656,878 | 2005-03-01 | ||
| PCT/CA2006/000300 WO2006092049A1 (en) | 2005-03-01 | 2006-03-01 | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008531604A JP2008531604A (ja) | 2008-08-14 |
| JP2008531604A5 true JP2008531604A5 (https=) | 2011-01-27 |
| JP5154954B2 JP5154954B2 (ja) | 2013-02-27 |
Family
ID=36940808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557300A Expired - Fee Related JP5154954B2 (ja) | 2005-03-01 | 2006-03-01 | 選択的なグリコシダーゼインヒビター、インヒビターを作製する方法、およびインヒビターの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080287375A1 (https=) |
| EP (2) | EP2436687A1 (https=) |
| JP (1) | JP5154954B2 (https=) |
| CN (1) | CN101208352B (https=) |
| AU (1) | AU2006220187B2 (https=) |
| CA (2) | CA2819464A1 (https=) |
| WO (1) | WO2006092049A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080166323A1 (en) * | 2004-04-14 | 2008-07-10 | Uab Research Foundation | Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock |
| EP2057171A4 (en) * | 2006-08-31 | 2010-04-21 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF |
| CN107253970A (zh) * | 2006-08-31 | 2017-10-17 | 西蒙·弗雷瑟大学 | 选择性糖苷酶抑制剂及其用途 |
| GB0622702D0 (en) * | 2006-11-15 | 2006-12-27 | Univ Dundee | Selective glycosidase inhibitors |
| US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
| CA2732335A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| EP2321289A4 (en) * | 2008-08-01 | 2011-11-16 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE |
| CA2737267A1 (en) * | 2008-09-16 | 2010-04-08 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
| US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
| WO2012040719A2 (en) * | 2010-09-24 | 2012-03-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders |
| TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| US8933040B2 (en) | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
| US8901087B2 (en) * | 2010-11-08 | 2014-12-02 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) * | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
| DK2655388T3 (en) * | 2010-12-23 | 2016-09-19 | Alectos Therapeutics Inc | Selective glykosidaseinhibitorer and uses thereof |
| WO2012126091A1 (en) * | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129651A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129802A1 (en) * | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof |
| WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| CN103889996B (zh) * | 2011-06-27 | 2016-02-03 | 阿列科托斯治疗有限公司 | 选择性糖苷酶抑制剂及其用途 |
| WO2013000085A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2744338B1 (en) * | 2011-08-18 | 2016-04-27 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| AU2012298949B2 (en) * | 2011-08-25 | 2016-09-22 | Merck Patent Gmbh | Pyrano [3, 2 - D] [1, 3] thiazole as glycosidase inhibitors |
| KR102108586B1 (ko) | 2012-05-08 | 2020-05-07 | 머크 샤프 앤드 돔 코포레이션 | 투과성 글리코시다제 억제제 및 그의 용도 |
| WO2014032185A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2014032188A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2014052453A1 (en) | 2012-09-25 | 2014-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
| WO2014067003A1 (en) | 2012-10-31 | 2014-05-08 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| WO2014171206A1 (ja) * | 2013-04-17 | 2014-10-23 | Yuasa Tomoyuki | 糖尿病治療薬の新規なスクリーニング方法 |
| EP3868752A1 (en) | 2014-08-28 | 2021-08-25 | Asceneuron SA | Glycosidase inhibitors |
| AU2017222958B2 (en) | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
| SG11201807012QA (en) | 2016-02-25 | 2018-09-27 | Asceneuron S A | Acid addition salts of piperazine derivatives |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| CN108884078A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| WO2019037860A1 (en) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | LINEAR INHIBITORS OF GLYCOSIDASE |
| IL280841B2 (en) | 2018-08-22 | 2024-12-01 | Asceneuron S A | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
| WO2020039027A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Pyrrolidine glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| CN114524854B (zh) * | 2022-02-25 | 2023-05-26 | 中国农业大学 | 一种糖基芳香环碳苷衍生物及其制备方法与应用 |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
| CN116376875B (zh) * | 2023-03-03 | 2024-02-23 | 云南师范大学 | 耐热性提高的n-乙酰氨基葡萄糖苷酶突变体及其应用 |
| CN116555229B (zh) * | 2023-05-25 | 2024-09-20 | 云南师范大学 | N-乙酰氨基葡萄糖苷酶突变体、重组表达载体及菌和应用 |
| CN118086249B (zh) * | 2024-01-24 | 2024-12-06 | 云南师范大学 | 一种协同提高酶活和热稳定性的n-乙酰氨基葡萄糖苷酶突变体及其制备与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818732D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| US6774140B1 (en) * | 1999-05-11 | 2004-08-10 | The Scripps Research Institute | Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| WO2002072860A1 (en) * | 2001-03-14 | 2002-09-19 | Denki Kagaku Kogyo Kabushiki Kaisha | Process for producing hyaluronic acid or its derivative |
| EP1633356A1 (en) * | 2003-05-22 | 2006-03-15 | The Hospital for Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| EP2057171A4 (en) * | 2006-08-31 | 2010-04-21 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF |
| EP2321289A4 (en) * | 2008-08-01 | 2011-11-16 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE |
| CA2732335A1 (en) * | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| CA2737267A1 (en) * | 2008-09-16 | 2010-04-08 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US9120781B2 (en) * | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US8933040B2 (en) * | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
| DK2655388T3 (en) * | 2010-12-23 | 2016-09-19 | Alectos Therapeutics Inc | Selective glykosidaseinhibitorer and uses thereof |
| WO2012126091A1 (en) * | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129651A1 (en) * | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
-
2006
- 2006-03-01 AU AU2006220187A patent/AU2006220187B2/en not_active Ceased
- 2006-03-01 EP EP11184538A patent/EP2436687A1/en not_active Withdrawn
- 2006-03-01 US US11/817,465 patent/US20080287375A1/en not_active Abandoned
- 2006-03-01 JP JP2007557300A patent/JP5154954B2/ja not_active Expired - Fee Related
- 2006-03-01 EP EP06705254A patent/EP1869060B1/en not_active Expired - Lifetime
- 2006-03-01 CN CN2006800149950A patent/CN101208352B/zh not_active Expired - Fee Related
- 2006-03-01 CA CA2819464A patent/CA2819464A1/en not_active Abandoned
- 2006-03-01 WO PCT/CA2006/000300 patent/WO2006092049A1/en not_active Ceased
- 2006-03-01 CA CA2599843A patent/CA2599843C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008531604A5 (https=) | ||
| JP7189983B2 (ja) | 異常炎症反応に関連する状態を処置するための方法および組成物 | |
| ES2875824T3 (es) | Composiciones de solución sólida y su uso en la inflamación crónica | |
| JP2009536191A5 (https=) | ||
| US20110224196A1 (en) | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent | |
| JP2009102342A5 (https=) | ||
| JP2011057693A5 (https=) | ||
| JP2007533625A5 (https=) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2006503850A5 (https=) | ||
| ES2449340T3 (es) | Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| US20260027139A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| JP2014510782A5 (https=) | ||
| WO2009149166A3 (en) | Methods and compositions for the diagnosis and treatment of proliferative disorders | |
| RU2006141647A (ru) | Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний | |
| RU2006141276A (ru) | Производное пурина | |
| JP2008500378A5 (https=) | ||
| RU2007138582A (ru) | Пероральные дозированные формы производных гемцитабина | |
| WO2007054348A1 (de) | Neue arzneimittel | |
| ES2526398T3 (es) | Composiciones inhibidoras de la recaptación de serotonina-norepinefrina para tratar el dolor crónico | |
| CN1842328A (zh) | 可用作抗炎剂的α－氨基酰胺衍生物 | |
| JP2006514063A5 (https=) | ||
| US9073884B2 (en) | Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them | |
| EP4108240A3 (en) | Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3 |